John A. Fry MD, FACC, FSCAI

3.2K posts

John A. Fry MD, FACC, FSCAI banner
John A. Fry MD, FACC, FSCAI

John A. Fry MD, FACC, FSCAI

@JohnAFryMD

Interventional Cardiology Complex and High Risk PCI Preventive Cardiology Tweets =my own

Charelston, SC Katılım Mart 2010
304 Takip Edilen706 Takipçiler
John A. Fry MD, FACC, FSCAI retweetledi
American Heart Association
American Heart Association@American_Heart·
The American Heart Association mourns the passing of the legendary cardiologist Eugene Braunwald, M.D., widely recognized as one of the most influential figures in the history of cardiovascular medicine. Over seven decades, his work reshaped the understanding and treatment of heart disease, leading many to call him the father of modern cardiology. Braunwald was a lifelong contributor to the American Heart Association, helping advance its research and scientific mission, and was honored with some of the Association’s highest honors for his lasting influence on cardiovascular care and research. His influence extended well beyond his own discoveries, as generations of Association‑supported investigators, clinicians and academic leaders were trained by Braunwald or guided by the clinical trial standards and mentorship models he helped establish. newsroom.heart.org/news/american-…
English
68
897
2.2K
441.5K
John A. Fry MD, FACC, FSCAI
John A. Fry MD, FACC, FSCAI@JohnAFryMD·
@DrJayMohan Grew up with this wire! Everyone’s workhorse back in the day. Good product. I never use it now. Much better options available from Asahi as well as the Terumo Runthrough
English
0
0
1
369
John A. Fry MD, FACC, FSCAI retweetledi
Circulation
Circulation@CircAHA·
#SimPub #ACC26 HEPARIN STEMI RCT: Pre-hospital UFH at first medical contact improved pre-PCI TIMI 2-3 flow without excess bleeding. Supports routine prehospital anticoagulation in STEMI referred for primary PCI. @DaniloFrancoMD ahajrnls.org/4theyfI
Circulation tweet media
English
1
25
51
9.2K
John A. Fry MD, FACC, FSCAI retweetledi
American College of Cardiology
SMART-DECISION: Discontinuing beta-blocker therapy was found to be noninferior to continuing the therapy among stable, low-risk patients who took it for at least one year following a #cvMI. Get the latest insights from the #ACC26 LBCT: bit.ly/4bPRayM
American College of Cardiology tweet media
English
0
14
37
5.2K
John A. Fry MD, FACC, FSCAI retweetledi
NEJM
NEJM@NEJM·
Presented at #ACC26: Among patients with a preserved ejection fraction at least 1 year after myocardial infarction, stopping beta-blockers was noninferior to continuing therapy with respect to major clinical outcomes. Full SMART-DECISION trial results: nejm.org/doi/full/10.10… @ACCinTouch
NEJM tweet media
English
0
149
444
35.6K
John A. Fry MD, FACC, FSCAI retweetledi
NEJM
NEJM@NEJM·
Presented at #ACC26: In the ALL-RISE trial, FFRangio (fractional flow reserve derived from angiography) was noninferior to pressure-wire–guided assessment in reducing risk among patients with intermediate coronary stenosis. Full trial results: nejm.org/doi/full/10.10… Editorial: Toward Broader Adoption of Coronary Physiological Assessment nejm.org/doi/full/10.10… @ACCinTouch
NEJM tweet media
English
1
48
121
33.2K
John A. Fry MD, FACC, FSCAI retweetledi
JACC Journals
JACC Journals@JACCJournals·
In patients with symptomatic single-vessel chronic total occlusion, percutaneous coronary intervention for coronary chronic total occlusion (CTO PCI) improves angina beyond placebo. Get the details in #JACC: jacc.org/doi/10.1016/j.… #ACC26 #PCI #CTO @dr_skhan1
JACC Journals tweet media
English
1
64
134
20.5K
John A. Fry MD, FACC, FSCAI retweetledi
NEJM
NEJM@NEJM·
Presented at #ACC26: Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results: nejm.org/doi/full/10.10… Editorial: Paving the Road toward Targeted Lipid Lowering nejm.org/doi/full/10.10… @ACCinTouch
NEJM tweet media
English
13
280
759
183K
John A. Fry MD, FACC, FSCAI retweetledi
American College of Cardiology
#ACC26: 🆕 Insights from the CHAMPION-AF trial Device-based LAA closure was comparable to NOAC therapy in reducing the combined rate of death from CV causes, stroke, or systemic embolism at 3️⃣ years in pts w/ #AFib who were candidates for #cvCoag. More: bit.ly/4bIv5SA
American College of Cardiology tweet media
English
0
10
24
2.9K
John A. Fry MD, FACC, FSCAI retweetledi
C. Michael Gibson MD
C. Michael Gibson MD@CMichaelGibson·
STEMI-DTU trial: Combination of the Impella CP plus device a 30-minute delay to PCI did not reduce infarct size vs. immediate PCI in patients with anterior STEMI without shock. #ACC26 View slides here: clinicaltrialresults.org/wp-content/upl…
C. Michael Gibson MD tweet mediaC. Michael Gibson MD tweet mediaC. Michael Gibson MD tweet mediaC. Michael Gibson MD tweet media
English
3
46
111
25.5K
John A. Fry MD, FACC, FSCAI retweetledi
American College of Cardiology
RENOVATE-COMPLEX-PCI: #PCI guidance w/ intravascular imaging, compared w/ angiography was associated w/ a sustained risk reduction for the primary composite endpoint of target vessel failure in patients w/ complex coronary artery lesions. 🔗 bit.ly/40qACIy #JACC
American College of Cardiology tweet media
English
1
25
49
5.2K